Domestic first imitation: "heavy bomb class" anti lung cancer first-line drug gefitinib (IRICO) on the market!!

On February 18, the first successful imitation of Qilu pharmaceutical and the first-line target specific drug "heavy bomb" for the treatment of non-small cell lung cancer (IRICO) listing meeting and the establishment meeting of multidisciplinary diagnosis and treatment team Committee (MDT) were held in Nanjing The listing of domestic gefitinib has broken the monopoly pattern of foreign pharmaceutical giants in the Chinese market and greatly lowered the market price of products, which means that the treatment of non-small cell lung cancer has really entered the era of parity, greatly enhanced the availability of drugs, will greatly reduce the economic burden of patients' medicine, and can save billions of yuan for the national health insurance fund At the same time, the establishment of MDT Expert Committee of lung cancer will make the domestic lung cancer treatment enter the era of multi-disciplinary joint diagnosis and treatment mode, which is expected to greatly improve the level of diagnosis and treatment of lung cancer in China More than 150 top medical experts and scholars, including Yu Jinming, academician of Chinese Academy of engineering, Professor Shi Yuankai, Professor Chen Haiquan, Cancer Hospital Affiliated to Fudan University, Professor Wang Jun, people's Hospital of Peking University, and Professor Jiao Shunchang, Chinese people's Liberation Army, attended the conference At the meeting, Ms Li Yan, general manager of Qilu pharmaceutical, Professor Yang Guoping, an authoritative expert in clinical evaluation of domestic drugs and professor of clinical pharmacology of Central South University, delivered speeches successively Li Yan first extended a warm welcome to all the experts and media reporters present She said that as an enterprise that has taken the revitalization of the national pharmaceutical industry as its responsibility, Qilu pharmaceutical has been focusing on the research and development of high-level new drugs for a long time, in order to continuously increase the availability of drugs for patients, so that the people can afford to see the disease and treat it well The successful listing of domestic gefitinik is the latest technology crystallization under the guidance of this concept "In the industry evaluation, gefitinik is" a gift from God to Asian people " I hope that the listing of irik is a gift from Qilu to Chinese patients, which is the most real thing Qilu people do to repay the society." Aiming at the big drugs with good curative effect and urgent need of the common people, Qilu pharmaceutical has been racing against time and constantly strengthening scientific research Since the 1980s, a large number of new drugs and special drugs have been developed successively in the fields of anti infection, anti-tumor, cardio cerebrovascular, mental and neurology Tens of millions of patients have relieved their pain "Pharmacy is a matter of curing diseases and saving people We always take" to be the best medicine to express our love "as our mission and strive to practice it Qilu people understand that "good medicine" is based on the belief of loyalty to the quality of drugs, adhering to the concept of "one millionth of the enterprise is one hundred percent of the patients", so as to make the drugs safer; it is to use the latest technical means to make the drugs more effective and cheaper, so as to make the drug experience of the patients more humanized and dignified! " Li Yan said In his speech, Professor Yang Guoping introduced in detail the clinical consistency evaluation process of IRICO, and published the evaluation conclusion: IRICO has deep equivalence with the original research drug and can be used equally He spoke highly of Qilu pharmaceutical's high-level realization of gefitinib in a short period of time "I've worked with Qilu pharmaceutical for many years, and I'm very convinced of their work philosophy and way of doing things The first successful imitation of gefitinib is inseparable from their great emphasis on research norms and high-level research quality," he said It is understood that domestic gefitinib is the product of national "12th Five Year Plan", "major scientific and technological special project of major new drug creation" and "research, development and industrialization of major anti-tumor drug varieties urgently needed in clinical practice" The successful launch of this new drug lasted six years, and it has won four national invention patents, which can be regarded as a typical case of high-speed, high-quality and high-efficiency drug research and development in the industry Qilu pharmaceutical therefore obtained the certificate of industrialization demonstration project of national torch plan According to Dr Guan Kailin, vice president of Qilu Pharmaceutical Research Institute, since the establishment of the project in 2010, the R & D team has carried out relevant research in accordance with international standards; selected the most authoritative and high-quality drug clinical experiment base in China, and carried out strict clinical experiments in accordance with the way of international integration; the first application, during which it experienced the most severe "722 clinical verification" in China, IRICO The first one-time zero defect was approved through clinical verification Guan Kailin said that in order to make the country's major scientific and technological achievements benefit every patient and maximize the accessibility of drugs, Qilu pharmaceutical decided to launch a drug donation plan According to the plan, free medicine will be given to patients after 8 months of self medication and accumulating 24 boxes; minimum living insurance patients will receive up to 8 months and accumulating 24 boxes of free medicine At present, the plan has been put into effect As an important agenda of the conference, the organizers of the conference also held a grand ceremony for the establishment of MDT Committee Yu Jinming, academician of Chinese Academy of engineering and President of Shandong Cancer Hospital, Shi Yuankai, deputy director of National Cancer Center and professor of Cancer Hospital of Chinese Academy of Medical Sciences jointly inaugurated MDT According to academician Yu Jinming, the MDT Committee for lung cancer was established to gather ideas and ideas for the treatment and progress of lung cancer through the authoritative experts in the field of lung cancer in the United Nations, gather the strength of multiple disciplines, and conspire for the welfare of patients At the same time, it also aims to further strengthen interdisciplinary exchanges and promote cooperation and sharing among specialties Before the reception ceremony, Professor Shi Yuankai read out the member list of the first MDT Expert Committee of lung cancer The committee is composed of 85 lung cancer diagnosis and treatment experts and scholars from major hospitals, universities and scientific research institutions in China, with Academician Yu Jinming as the team leader and Professor Shi Yuankai as the deputy team leader   The multi-disciplinary diagnosis and treatment model originated in the 1990s The United States first proposed this concept, that is, a working group composed of experts from general surgery, oncology, radiotherapy, Radiology, pathology, endoscopy center and other departments For a disease, through regular meetings, we proposed the best treatment plan for patients, and then the relevant disciplines alone or jointly implemented the concept Treatment plan Yu Jinming said frankly that in the past 20 years, the clinical treatment effect of lung cancer is not satisfactory People are more and more aware that the diagnosis and treatment mode of lung cancer with single discipline as the main single combat has lagged behind the development of the times Yu believes that through the establishment of MDT Expert Committee and the establishment of a multi-disciplinary joint diagnosis and treatment platform, the treatment level of lung cancer in China will continue to improve and reach a satisfactory level In addition, the conference also held two academic exchanges, one for lung cancer diagnosis and treatment and the other for case sharing